Interstitial Lung Diseases (ILDs) represent a heterogeneous group of pathologies, which
may be related to different causes. A low percentage of these lung diseases may be …

Drug-induced infiltrative lung disease may manifest as variable clinical radiological patterns,
including subacute or chronic interstitial pneumonia, pulmonary fibrosis, eosinophilic …

AIM: To compare the parenchymal high-resolution computed tomography (HRCT)
appearances with histological findings in patients with drug-induced lung disease and to …

Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly
common cause of morbidity and mortality. The number of drugs associated with the …

Drugs can have multiple different adverse effects on the lungs, airways, pleura,
mediastinum, and the interstitium. Their appearance can mimic other interstitial lung …

With an increasing number of therapeutic drugs, the list of drugs that is responsible for
severe pulmonary disease also grows. Many drugs have been associated with pulmonary …

Infiltrative lung diseases, or more broadly diffuse parenchymal lung diseases, encompass a
wide and heterogeneous group of disease processes characterised by diffuse lung …

Numerous agents, including cytotoxic and noncytotoxic drugs, have the potential to affect the
lungs adversely. Since the initial reports in the early 1970s, drug-induced lung injury has …

Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be
difficult to distinguish from a number of illnesses that commonly occur in patients with non …

The term interstitial lung disease (ILD) comprises more than 200 separate disease entities,
each having its separate and often unique radiological manifestations. Because the clinical …